Hoffmann, Michèle; Hayoz, Stefanie; Özdemir, Berna C. (2022). Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma-A Real World Single-Center Analysis. Biology, 11(3) MDPI 10.3390/biology11030422
|
Text
biology-11-00422.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (998kB) | Preview |
Approved adjuvant treatment options for stage III melanoma are the immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab, and in presence of a BRAF V600E/K mutation additionally dabrafenib in combination with trametinib (BRAFi/MEKi). This study aims to describe prescription patterns and recurrence and toxicity rates of adjuvant-treated melanoma patients from the Cancer Center of the University Hospital Bern, Switzerland. One hundred and nine patients with an indication for adjuvant treatment were identified. Five (4.6%) had contraindications and, as such, were not proposed any adjuvant treatment, while 10 patients (9.2%) declined treatment. BRAF status was known for 91 (83.5%) patients. Of 40 (36.7%) patients with BRAF V600E/K melanoma, pembrolizumab was prescribed to 18 (45.0%), nivolumab to 16 (40.0%), and dabrafenib/trametinib to three (7.5%) patients. Grade 3-4 toxicity was reported in 18.9% and 16.7% of all the patients treated with pembrolizumab and nivolumab, respectively. No toxicities were observed for dabrafenib/trametinib. Thirty-eight percent of the patients treated with pembrolizumab and 40.0% of those treated with nivolumab relapsed. No relapses were reported for dabrafenib/trametinib. Prescription patterns indicate a clear preference for adjuvant ICI treatment.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Hoffmann, Michèle, Özdemir, Berna |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2079-7737 |
Publisher: |
MDPI |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
28 Mar 2022 11:43 |
Last Modified: |
05 Dec 2022 16:17 |
Publisher DOI: |
10.3390/biology11030422 |
PubMed ID: |
35336796 |
Uncontrolled Keywords: |
BRAF inhibitor adjuvant treatment anti-PD1 clinical practice immune checkpoint inhibitor melanoma preferences prescription pattern real world recurrence relapse toxicity |
BORIS DOI: |
10.48350/168182 |
URI: |
https://boris.unibe.ch/id/eprint/168182 |
Actions (login required)
 |
Edit item |